Nucleoside analogue delivery systems in cancer therapy.
Nucleoside analogues (NAs) are important agents in the treatment of hematological malignancies. They are prodrugs that require activation by phosphorylation. Their rapid catabolism, cell resistance and overdistribution in the body jeopardize nucleoside analogue chemotherapy. Accordingly, therapeutic doses of NAs are particularly high and regularly have to be increased, resulting in severe toxicity and narrow therapeutic index. The major challenge is to concentrate the drug at the tumour site, avoiding its distribution to normal tissues. New drug carriers and biomaterials are being developed to overcome some of these obstacles. This review highlights novel NA delivery systems and discusses new technologies that could improve NA cancer therapy.
Diab
Roudayna
R
School of Pharmacy, Université Lyon 1-ESCPE - UMR 5007, Laboratoire d'Automatique et de Génie des Procédés, Bât. 308 G, 43, Bd du 11 Novembre 1918, 69622 Villeurbanne Cedex, France.
Degobert
Ghania
G
Hamoudeh
Misara
M
Dumontet
Charles
C
Fessi
Hatem
H
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D009705:Nucleosides / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D011355:Prodrugs; D013678:Technology, Pharmaceutical
D000970:Antineoplastic Agents; D004337:Drug Carriers; D009705:Nucleosides; D011355:Prodrugs